Guardian Pharmacy Services (NYSE:GRDN) Upgraded at Wall Street Zen

Key Points

• Guardian Pharmacy Services (NYSE:GRDN) has received an upgrade from a "hold" rating to a "strong-buy" rating from Wall Street Zen, signaling positive confidence from analysts.
• Truist Financial and Raymond James have set a price target of $28.00 for the stock, reflecting an increase from previous targets.
• Recent insider activity includes significant share sales by directors, with a total of 11.34 million shares sold in the last three months, amounting to over $228 million.

Wall Street Zen upgraded shares of Guardian Pharmacy Services (NYSE:GRDN - Free Report) from a hold rating to a strong-buy rating in a research note released on Sunday morning.

Other equities research analysts have also recently issued reports about the stock. Truist Financial restated a "buy" rating and set a $28.00 price objective (up from $25.00) on shares of Guardian Pharmacy Services in a research note on Monday, May 19th. Raymond James Financial set a $28.00 price objective on shares of Guardian Pharmacy Services and gave the stock an "outperform" rating in a report on Wednesday, May 14th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $25.67.

Guardian Pharmacy Services Stock Performance

Shares of GRDN traded up $0.5670 during midday trading on Friday, hitting $25.9670. 76,016 shares of the stock traded hands, compared to its average volume of 163,010. Guardian Pharmacy Services has a 1-year low of $14.16 and a 1-year high of $26.91. The firm has a market capitalization of $1.64 billion and a PE ratio of -17.03. The business's 50 day moving average price is $20.92 and its two-hundred day moving average price is $21.53.

Insider Activity

In other Guardian Pharmacy Services news, insider Fred Burke sold 138,705 shares of the business's stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $20.16, for a total transaction of $2,796,292.80. Following the sale, the insider owned 413,019 shares in the company, valued at approximately $8,326,463.04. The trade was a 25.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David K. Morris sold 68,547 shares of the firm's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $20.16, for a total transaction of $1,381,907.52. Following the completion of the transaction, the insider directly owned 214,495 shares of the company's stock, valued at $4,324,219.20. This represents a 24.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,344,912 shares of company stock worth $228,713,426. 63.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Guardian Pharmacy Services

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GRDN. BNP Paribas Financial Markets acquired a new position in Guardian Pharmacy Services in the 4th quarter worth approximately $37,000. Parkside Financial Bank & Trust acquired a new position in Guardian Pharmacy Services in the 2nd quarter worth approximately $41,000. Raymond James Financial Inc. purchased a new position in Guardian Pharmacy Services during the 2nd quarter valued at about $43,000. Police & Firemen s Retirement System of New Jersey grew its stake in Guardian Pharmacy Services by 76.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company's stock valued at $52,000 after acquiring an additional 1,062 shares in the last quarter. Finally, State of Wyoming purchased a new position in Guardian Pharmacy Services during the 2nd quarter valued at about $58,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.